CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Advanced Cell Diagnostics has entered into an agreement with Johns Hopkins University on behalf of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, whereby ACD’s RNAscope technology will be used to validate novel biomarkers and drug targets for cancer immunotherapy.
Cancer immunotherapy has been gaining momentum, with the FDA approval of anti-CTLA-4 therapy for melanoma and with the recent durable remissions produced by targeting PD1 in multiple solid tumors in early-phase clinical trials led by Johns Hopkins investigators. With many additional immune modulatory molecules identified for targeting that play chief roles in specific subsets of cancer, it will be critical to develop standardized biomarkers to guide the application of immune therapies on a patient-by-patient basis.